The anticancer activity of the 2ME-loaded zeolite nanoparticles was assessed determining the effect of this nanocomposite on the viability of the human prostate cancer cell line LNCaP, and assessing whether the 2ME-loaded zeolite nanoparticles mimic the effect of 2ME on the expression of the mRNA for SPON1 in LNCaP cells. The gene discussed is SPON1; the disease is prostate cancer.